Cellectar Biosciences (CLRB) News Today $2.29 -0.08 (-3.38%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 9:20 AM | marketbeat.comRoth Capital Analysts Lower Earnings Estimates for Cellectar Biosciences, Inc. (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Analysts at Roth Capital cut their FY2028 EPS estimates for shares of Cellectar Biosciences in a research report issued on Wednesday, July 24th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will post earniJuly 26 at 4:47 AM | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Share Price Passes Below 200 Day Moving Average of $3.30Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average of $3.30July 26 at 2:27 AM | markets.businessinsider.comBuy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial OutlookJuly 25 at 10:37 AM | seekingalpha.comCellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call TranscriptJuly 23, 2024 | benzinga.comCancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer StudyJuly 23, 2024 | seekingalpha.comCellectar: WM Treatment Data Leads To A Few Regulatory MilestonesJuly 23, 2024 | msn.comCellectar falls after updating pivotal data for lead assetJuly 23, 2024 | globenewswire.comCellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 MonthsJuly 22, 2024 | globenewswire.comCellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 MillionJuly 22, 2024 | globenewswire.comCellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 MillionJuly 18, 2024 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Shares Cross Below Two Hundred Day Moving Average of $3.31July 18, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average of $3.31Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average of $3.31July 2, 2024 | marketbeat.comShort Interest in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Expands By 9.2%Cellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,370,000 shares, a growth of 9.2% from the May 31st total of 2,170,000 shares. Approximately 6.8% of the company's stock are short sold. Based on an average daily volume of 684,700 shares, the days-to-cover ratio is currently 3.5 days.June 27, 2024 | globenewswire.comCellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market LandscapeJune 12, 2024 | marketbeat.comADAR1 Capital Management LLC Takes $3.82 Million Position in Cellectar Biosciences, Inc. (NASDAQ:CLRB)ADAR1 Capital Management LLC acquired a new stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,378,082 shares of the biopharmaceutical company's stock, valMay 29, 2024 | globenewswire.comCellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis FungoidesMay 27, 2024 | marketbeat.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Holdings Increased by AIGH Capital Management LLCAIGH Capital Management LLC raised its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) by 182.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,915,220 shares of theMay 24, 2024 | msn.comCellectar Biosciences files for $300M mixed securities shelfMay 22, 2024 | finance.yahoo.comIs Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?May 20, 2024 | marketbeat.comWorth Venture Partners LLC Buys 414,786 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB)Worth Venture Partners LLC grew its stake in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) by 148.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 693,909 shares of the biopharmaceutical company's sMay 20, 2024 | seekingalpha.comCellectar Biosciences: Still Working On That Hit (Maintain Buy)May 16, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug PipelineMay 16, 2024 | marketbeat.comRoth Capital Equities Analysts Lift Earnings Estimates for Cellectar Biosciences, Inc. (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities research analysts at Roth Capital raised their Q2 2024 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Tuesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the biopharMay 15, 2024 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call TranscriptMay 15, 2024 | marketbeat.comCellectar Biosciences, Inc. to Post FY2026 Earnings of $0.97 Per Share, Roth Capital Forecasts (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Investment analysts at Roth Capital raised their FY2026 EPS estimates for Cellectar Biosciences in a report released on Tuesday, May 14th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn $0.97 per sMay 15, 2024 | finance.yahoo.comCellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Cellectar Biosciences Inc Earnings CallMay 14, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024May 14, 2024 | markets.businessinsider.comCellectar Biosciences Inc Loss At -$21.58 Mln In Q1May 14, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate UpdateMay 8, 2024 | marketbeat.comCellectar Biosciences (CLRB) to Release Earnings on TuesdayCellectar Biosciences (NASDAQ:CLRB) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 8, 2024 | globenewswire.comCellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 7, 2024 | globenewswire.comCellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024May 2, 2024 | morningstar.comCellectar Biosciences Inc CLRBApril 19, 2024 | seekingalpha.comCLRB Cellectar Biosciences, Inc.April 14, 2024 | marketbeat.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest UpdateCellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,530,000 shares, an increase of 34.6% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 1.4 days. Currently, 8.7% of the shares of the company are short sold.April 9, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above 50 Day Moving Average of $3.73Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above Fifty Day Moving Average of $3.73March 29, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid FinancialsMarch 29, 2024 | nz.finance.yahoo.comJeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th BirthdayMarch 29, 2024 | finance.yahoo.comCellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?March 28, 2024 | finance.yahoo.comQ4 2023 Cellectar Biosciences Inc Earnings CallMarch 27, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023March 27, 2024 | msn.comCellectar Biosciences FY 2023 Earnings PreviewMarch 27, 2024 | benzinga.comEarnings Preview For Cellectar BiosciencesMarch 27, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate UpdateMarch 20, 2024 | globenewswire.comCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024March 14, 2024 | globenewswire.comCellectar Biosciences to Present at the 36th Annual Roth ConferenceMarch 4, 2024 | globenewswire.comCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck CancerFebruary 22, 2024 | benzinga.comCellectar Biosciences Stock (NASDAQ:CLRB), Short Interest ReportFebruary 15, 2024 | money.usnews.comCellectar Biosciences Inc Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of cash before the Fed's next meeting (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview CLRB Media Mentions By Week CLRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.150.61▲Average Medical News Sentiment CLRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼121▲CLRB Articles Average Week Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INZY News ALXO News NKTX News KMDA News XOMA News MGNX News AVIR News AMRN News ADCT News VRCA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.